PT - JOURNAL ARTICLE AU - Jee, Justin AU - Stonestrom, Aaron J. AU - Devlin, Sean AU - Nguyentran, Teresa AU - Wills, Beatriz AU - Narendra, Varun AU - Foote, Michael B. AU - Lumish, Melissa AU - Vardhana, Santosha AU - Pastores, Stephen M. AU - Korde, Neha AU - Patel, Dhwani AU - Horwitz, Steven AU - Scordo, Michael AU - Daniyan, Anthony TI - Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19 AID - 10.1101/2020.08.11.20145458 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.11.20145458 4099 - http://medrxiv.org/content/early/2020/08/12/2020.08.11.20145458.short 4100 - http://medrxiv.org/content/early/2020/08/12/2020.08.11.20145458.full AB - Background Corticosteroids, anti-CD20 agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer. How these agents impact patients with cancer who are infected with SARS-CoV-2 remains unclear.Methods We retrospectively investigated associations between SARS-CoV-2-associated respiratory failure or death with receipt of the aforementioned medications and with pre-COVID-19 neutropenia. The study included all cancer patients diagnosed with SARS-CoV-2 at Memorial Sloan Kettering Cancer Center until June 2, 2020 (N=820). We controlled for cancer-related characteristics known to predispose to worse COVID-19. To address that more acutely ill patients receive therapeutic corticosteroids, we examined patient subsets based on different levels of respiratory support: ≤2 L/min supplemental oxygen, >2L/min supplemental oxygen, and advanced respiratory support prior to death.Results Corticosteroid administration was associated with worse outcomes in the pre-2L supplemental oxygen cohort; no statistically significant difference was observed in the >2L/min supplemental oxygen and post-critical cohorts. Interleukin-6 (IL-6) and C-reactive protein (CRP) levels were lower, and ferritin levels were higher, after corticosteroid administration. In patients with metastatic thoracic cancer, 9 of 25 (36%) and 10 of 31 (32%) had respiratory failure or death among those who did and did not receive immunotherapy, respectively. Seven of 23 (30%) and 52 of 187 (28%) patients with hematologic cancer had respiratory failure or death among those who did and did not receive anti-CD20 therapy, respectively. Chemotherapy itself was not associated with worse outcomes, but pre-COVID-19 neutropenia was associated with worse COVID-19 course. Relative prevalence of chemotherapy-associated neutropenia in previous studies may account for different conclusions regarding the risks of chemotherapy in patients with COVID-19. In the absence of prospective studies and evidence-based guidelines, our data may aid providers looking to assess the risks and benefits of these agents in caring for cancer patients in the COVID-19 era.Competing Interest StatementJJ has a patent licensed by MDSeq Inc. AJS holds shares in Aprea Therapeutics and Editas Medicine and his spouse works for and receives salary support from BluePrint Research Group and in the course of her position consults for multiple pharmaceutical companies. SAV has received honoraria from Agios Pharmaceuticals and Rheos Pharmaceuticals, is an advisor for Immunai and has consulted for ADC Therapeutics. SP has received research funding from the Marcus Foundation and from bioMerieux. NK has received research funding from Amgen and has served on an advisory board for Astra Zeneca. MS has served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation. He received research funding from Angiocrine Bioscience, Inc. He served on an ad hoc advisory board for Kite - A Gilead Company. SH has received research support from ADC Therapeutics, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, Verastem, Portola Pharmaceuticals, and Trillium Therapeutics and has served as a consultant for ADC Therapeutics, C4 Therapeutics, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, and Trillium Therapeutics.Funding StatementThis research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 and by the Memorial Sloan Kettering Cancer Center K12 Paul Calabresi Career Development Award for Clinical Oncology (to A.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Memorial Sloan Kettering Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request